This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Active Biotech's Partner Teva Initiates A Further Clinical Trial In Multiple Sclerosis

Stocks in this article: ACTI

LUND, Sweden, Nov. 4, 2013 (GLOBE NEWSWIRE) --

Active  Biotech  (NASDAQ  OMX NORDIC: ACTI)
announced  today  that  its  partner  Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA)  will  initiate  a  further  clinical  trial,  LIBRETTO,  to  evaluate the
efficacy,  safety and tolerability of two doses of oral laquinimod (0.6 and 1.2
mg/day),  compared to  interferon beta-1a, in  patients with relapsing remitting
multiple  sclerosis. Primary  endpoint of  the study  will be brain atrophy. For
further  details please see  www.clinicaltrials.gov where the  trial will appear
during this week.

About laquinimod
Laquinimod  is an oral, investigational, CNS-active immunomodulator with a novel
mechanism  of action being developed for the treatment of relapsing-remitting MS
(RRMS).  The  global  Phase  III  clinical  development  program evaluating oral
laquinimod  in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase
III  laquinimod trial, CONCERTO, is evaluating  two doses of the investigational
product  (0.6mg and 1.2mg) in approximately  1,800 patients for up to 24 months.
The  primary outcome measure will be time to confirmed disability progression as
measured by the EDSS.

In  addition to the  MS clinical studies,  laquinimod has concluded  Phase II of
development  for  Crohn's  disease  and  lupus  nephritis.   Further studies are
planned  to determine the effectiveness of  laquinimod in treating patients with
Huntington's disease and Alzheimer's disease.

About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In  addition,  laquinimod  has  concluded  Phase  II development for Crohn's and
Lupus.  The company also has one additional project in clinical development, the
orally  administered compound paquinimod  (57-57) for systemic sclerosis. Please
visit www.activebiotech.com for more information.



For further information:

Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95
tomas.leanderson@activebiotech.com

  Active Biotech AB (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund
  Tel: +46 46 19 20 00
  Fax: +46 46 19 11 00

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act
This  press release  contains certain  forward-looking statements. Such forward-
looking  statements  involve  known  and  unknown risks, uncertainties and other
important   factors   that  could  cause  the  actual  results,  performance  or
achievements  of the company, or industry results, to differ materially from any
future  results,  performance  or  achievement  implied  by  the forward-looking
statements.  The company does not undertake any obligation to update or publicly
release   any   revisions  to  forward-looking  statements  to  reflect  events,
circumstances or changes in expectations after the date of this press release.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was provided to the media for publication 08:30 am CET on November 4, 2013.

Active Biotech's partner Teva initiates a further clinical trial : http://hugin.info/1002/R/1740139/584195.pdf

[HUG#1740139]

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs